Clinical trials: Relapsed/Refractory
CNS Lymphoma
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
This single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing orelabrutinib on the basis of rituximab and chemotherapy in treating patients with relapsed or refractory B-cell…
- Trial name
- NCT05926427
- Testing
- Orelabrutinib, Rituximab, Chemotherapy
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment
RATIONALE: Drugs used in chemotherapy, such as fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00845104
- Testing
- fludarabine phosphate, rituximab, bevacizumab
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Glioblastomas, Sarcoma
Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers
Background: People cope with cancer in different ways. Mindfulness means focusing on the present moment with an open mind. Researchers want to see if this can help children and young adults with a high-grade high-risk cancer with…
- Conditions
- Glioblastomas, Sarcoma, Astrocytoma, Brain Cancer
- Trial name
- NCT03538587
- Testing
- Enhanced Mindfulness Intervention, Psychoeducation
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
Docetaxel - Carboplatin As Second Line Treatment in Patients with Small Cell Lung Cancer
Phase II studies with docetaxel in first line - and second line treatment of SCLC demonstrated that docetaxel is an active agent in these patient groups.
- Trial name
- DOCAR (NCT00686985)
- Testing
- Carboplatin, docetaxel
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Dr. B. Biesma
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01076270
- Testing
- plerixafor, filgrastim, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine whether the combination of bevacizumab and bortezomib have increased efficacy in the treatment of relapsed/ refractory multiple myeloma.
- Trial name
- NCT00464178
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
RATIONALE: The influenza vaccine may help prevent flu in patients who have undergone stem cell transplant. PURPOSE: This clinical trial is studying how well the influenza vaccine works in preventing flu in patients who have…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00952185
- Testing
- cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Trial name
- NCT03196414
- Testing
- CART-138/BCMA/19/more
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
- Conditions
- Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
- Trial name
- NCT05595447
- Testing
- Brentuximab Vedotin 50 MG [Adcetris]
- Where
- Mexico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospital Regional de Alta Especialidad del Bajio
Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT03583424
- Testing
- Carmustine, Cytarabine, Etoposide
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Immunotherapy, Refractory Leukemia
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
This is an single center, single arm, phase 3 study to evaluate efficacy and safety of PD-1 Inhibitor combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen for patients with relapsed and refractory acute…
- Conditions
- Immunotherapy, Refractory Leukemia, Relapsed Adult AML, Acute Myeloid Leukemia
- Trial name
- NCT04722952
- Testing
- Visilizumab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
This is a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. The initial patients on the dose-finding portion of this study will be enrolled through a single institution.
- Trial name
- NCT00536575
- Testing
- Bortezomib, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- SCRI Development Innovations, LLC
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma Stage III, Multiple Myeloma Progression
- Trial name
- EPC-MM+L (NCT06485076)
- Testing
- Early Palliative Care
- Where
- Canada
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Multiple Myeloma, Non-Hodgkin Lymphoma
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT03019666
- Testing
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma, Refractory
Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific…
- Trial name
- NCT06242249
- Testing
- Anti-BCMA CAR-NK
- Where
- Iran
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
T Cell Lymphoma
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
This study will be a pilot study of sorafenib 400mg PO twice daily in refractory T-cell lymphomas including peripheral T-cell lymphoma (PTCL), angioimmunoblastic lymphadenopathy (AILD), cutaneous T cell lymphoma (CTCL)…
- Trial name
- NCT01561833
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
T-Cell and NK-Cell Neoplasm
A Global Study of the PETAL Consortium
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or…
- Trial name
- PETAL (NCT06067347)
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Relapsed or Refractory Lymphoma
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689
- Trial name
- NCT05602597
- Testing
- Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Advanced Cancer, Relapsed Cancer
Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
This study will evaluate the effects of human-animal interaction on reducing anxiety, depression, worry, and pain and enhancing quality of life in children ages 6-17 years old with a life threatening cancer and their parent…
- Conditions
- Advanced Cancer, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT04310345
- Testing
- Animal-Assisted Interactions
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center